A compound annual growth rate of 5.19% is predicted to propel the global market for neutropenia treatments from its 2022 valuation of USD 15.37 billion to USD 23.14 billion by 2030. The report looks at the factors driving, limiting, and challenging the global market for neutropenia treatments and how they affect demand throughout the course of the forecast period. Treatment options for neutropenia are also investigated.
Global Neutropenia Treatment Market: Overview
According to the Global Neutropenia Treatment Market Report, neutrophils, which aid in defending the body against infection, are in low concentrations in neutropenic patients. Both infections and cancer treatments can cause neutropenia. Neutropenia is classified as severe, moderate, or mild based on the amount of neutrophils in the blood sample. While therapy may not be necessary for many kinds of neutropenia, it is crucial for febrile neutropenia since it can be fatal.
Get a Free Sample : https://www.zionmarketresearch.com/sample/neutropenia-treatment-market
Global Neutropenia Treatment Market: Growth Factors
The increasing incidence of chemotherapy-induced neutropenia, the growing demand for effective and efficient treatment, and the accessibility of the medications through online pharmacies are the main drivers propelling the expansion of the global market. According to CDC data, around 650,000 cancer patients in the US get chemotherapy annually at an outpatient oncology clinic. Neutropenia, the most severe hematologic complication associated with chemotherapy-assisted cancer treatment, is a danger that these individuals have. Hospitalization, changes in treatment regimens, and occasionally even death result from this.
These and other causes, together with the rising incidence of autoimmune illnesses like lupus, Crohn’s disease, and rheumatoid arthritis, as well as infections like sepsis, hepatitis, and tuberculosis, are driving the rise of the global market for neutropenia treatments. Furthermore, an increase in pharmaceutical company mergers and acquisitions aimed at growing their businesses as well as an increase in the number of clinical trials for the treatment of neutropenia are some of the key drivers driving the growth of the global market.
In addition, significant expenditures on research and development as well as an increase in the outsourcing of drug discovery and development projects are driving the expansion of the worldwide market. Additionally, throughout the course of the forecast period, there may be multiple chances for the expansion of the global market for neutropenia treatment due to technical improvements that facilitate the creation of novel products for successful treatment. The regulatory organizations’ stringent rules for approval, however, might prevent the global market for neutropenia treatments from expanding too much.
The Covid-19 pandemic has a moderate impact on the global market for treatments for neutropenia. The production of medications and biologics required for the treatment of neutropenia has been impacted by the closure of manufacturing facilities, the temporary suspension of clinical trials, and the deferral of non-emergency cases as a result of the stringent lockdown and mobility restrictions in the first half of 2020. On the other hand, it is observed that the rise of the global market during the pandemic was supported by the decrease in platelet count in some Covid-19 positive patients and the online sales of medications.
Global Neutropenia Treatment Market: Segmentation
The global neutropenia treatment market is divided based on treatment, distribution channel, and region.
Based on treatment, the global neutropenia treatment market is split into antivirals, anti-fungals, antibiotics, and colony-stimulating factors. Among these, the colony-stimulating factor segment is anticipated to lead the global market due to the rise in focus of manufacturers on colony-stimulating factor-based drugs.
The distribution channel is bifurcated into online pharmacies, retail pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment is expected to hold the largest share in the market.
Global Neutropenia Treatment Market: Regional Analysis
During the projected period, North America is expected to hold a dominant position in the global market for neutropenia treatments. The main driver of the market’s expansion in this area is the rising incidence of chemotherapy-induced neutropenia, particularly in the US. Furthermore, the industry is expanding in North America due to the presence of cutting-edge technology, significant investments in research and development, and advantageous reimbursement regulations, among other reasons. According to estimates, the market’s fastest-growing area is Asia Pacific. This can be linked to rising healthcare costs, an increase in cancer cases, and an increase in the frequency of diseases in developing nations.
Directly Purchase a copy of the report with TOC @
Global Neutropenia Treatment Market: Competitive Players
- Teva Pharmaceutical Industries Ltd.
- Spectrum Pharmaceuticals
- Partner Therapeutics
- Novartis AG
- Mylan N.V.
- Cellerant Therapeutics
- Kyowa Kiri
Global Neutropenia Treatment Market: Segment Analysis
- Colony-Stimulating Factors
By Distribution Channel
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
- North America
- The U.S.
- The UK
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
What Reports Provides
- Full in-depth analysis of the parent market
- Important changes in market dynamics
- Segmentation details of the market
- Former, on-going, and projected market analysis in terms of volume and value
- Assessment of niche industry developments
- Market share analysis
- Key strategies of major players
- Emerging segments and regional markets
- Testimonials to companies in order to fortify their foothold in the market.
Contact Us :
Zion Market Research
USA/Canada Toll Free : 1 (855) 465-4651
Newark : 1 (302) 444-0166
India : +91 7768 006 007, +91 7768 006 008
Skype no : +13479038971, +17187054574
Skype no. United Kingdom : +442032894158
Blog : https://zmrblog.com/
read other reports :